Strides Pharma Science Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pzm7ocq19opopbbzcm0zijcz.pdf

Key Takeaways


The Ex-US Inflection

Badree Komandur: "Ex-US now stands shoulder to shoulder with the US, not instead of it but alongside it, and that makes Strides stronger as a whole."

US Business: Recovery with Margin Discipline

Badree Komandur: "We will not compromise on profitability or the quality of our business to chase revenue."

Differentiated Platforms: Nasal Sprays, Patches, Films


Margins: Compressed but Defended

Vikesh Kumar: "We did not want to launch products compromising our fabric of profitability discipline. And that is the reason we felt that it is better to protect the quality of margins and focus on profitability, drive the profitability and EPS margin accretion that we have been known for..."

Balance Sheet: Working Capital Swells, Normalization Expected


Sandoz Deal & Other Updates


Guidance & Commitments

CommitmentSpecificsTimeline
Overall FY28 revenue ambitionFully intact; regional mix shifts toward Ex-US contributing more than USFY28
US revenue aspiration (~$375M)Ambition unchanged, timing moved "a little beyond FY28"Beyond FY28
Ex-US revenue aspiration"Upwards of $375 million"FY28
H2 stronger than H1Reiterated; recent B2B wins and 4–6 US launches to underpin better H2H2 FY27
Sandoz deal closureAwaiting antitrust approval in few countriesQ3 FY27
First nasal spray approvalGDUFA goal date in H2 FY27Q4 FY27
Transdermal patch relaunchControlled-substance patch from Endo ANDAsQ3 FY27
First acquired-IP patch launchAcquired IP last yearLater this year
Gross margin range58% sustained at company levelOngoing
Cash conversion cycle improvementCash cycle engines "back in the next quarter itself"Coming quarters
Net debt-to-EBITDAExpected to stabilise and improve as inventory normalises and H2 launches contributeBy end of year
FY27 capex~₹300 croreFY27
FY28 capexSlightly lower than FY27; includes maintenance capex and intangiblesFY28
Differentiated products meaningful contributionSlight delay of 3–4 quarters; aiming for FY29By FY29
Bottom-line accelerationBottom line to accelerate ahead of top lineOngoing

Key Metrics

MetricQ2 FY27
Revenue₹1,429.7 crore, highest ever, +17% YoY and +13% QoQ
Ex-US revenue share~49% of total revenue, up from 43% in Q2 last year
Gross margin56.0%, vs 57.8% in Q2 last year and 60.9% in Q1; higher input costs
H1 gross margin58.3%, expected to be sustainable
EBITDA₹250.9 crore, +8% YoY, first time crossing ₹250 crore in a single quarter
EBITDA margin17.6%, vs 19.0% in Q2 last year and 18.2% in Q1
Operational PAT₹135.8 crore, +12% YoY
Operational EPS₹14.7, vs ₹13.2 in Q2 last year
Reported PAT₹134 crore; reported EPS ₹14.2 per share
US revenue₹685.5 crore ($73 million), +9% YoY and +9% QoQ
Ex-US revenue₹696.3 crore, +31% YoY; crossed US revenue for the first time
Ex-US as % of US102%, vs 76% in FY25 and 90% in FY26
Material costs44% of revenue, vs 42.2% in Q2 last year
Freight costs5.5% of revenue, up ₹21 crore YoY
Total operating costs38.4% of revenue, improved 40 bps
Depreciation and amortisation₹57 crore
Net finance cost₹43 crore; expected H2 range ₹40–45 crore
EBITDA to operational PAT conversion54%
Cash-to-cash cycle137 days, up 13 days from March 2026
Net debt-to-EBITDA ratio1.72x, reflecting ₹211 crore increase in net debt during H1 driven by working capital
Trailing 12-month ROCE14.4%, in the 14–15% range
ANDAs filed / approved230 filed, 212 approved as of October 2026, covering 154 products
Commercialised products75, up from 72 at end of Q1; 3 products launched in Q2
Top-3 market position products38 products, contributing ~70% of US revenue
Controlled Substances revenue share~6% of US revenue, from 5 commercialised products
Controlled Substances pipeline addressable market~$4.5 billion, ~6x the current ~$750 million market
Value-accretive pipeline products>40, with filings and approvals planned through FY30
Non-CS differentiated pipeline products>25
H1 FY27 revenue₹2,695 crore, +15.1%
H1 FY27 EBITDA₹481 crore, +6.9%; margin 17.8%
H1 FY27 operational PAT₹259 crore, +9.8%; operational EPS ₹28.1 per share
H1 FY27 reported PAT₹300 crore, +26.4%, includes gain on Pivot Path divestment
H1 FY27 capex and intangibles deployed₹208 crore
FY27 capex expected~₹300 crore
Expected H2 US launches4 to 6 products
Ex-US FY28 revenue aspirationUpwards of $375 million
US FY28 revenue aspiration~$375 million, now expected a little beyond FY28